Safety of Proton Pump Inhibitors in Pediatric Population: A Systematic Review.

IF 1.4 Q3 PEDIATRICS

Global Pediatric Health Pub Date : 2024-04-29 eCollection Date: 2024-01-01 DOI:10.1177/2333794X241248967

Deekshitha Alla, Dhruv Jayeshkumar Shah, Muneesh Seepana, Rishabh Baskara Salian, Sai Santhosha Mrudula Alla, Midhun Krishna Mohanan, Mert Sabıroğlu, Mohan Sai Sunith Vegesna, Aradhya Singh, Srajan Gupta, Shushrutha Shivalingappa Rekha

{"title":"Safety of Proton Pump Inhibitors in Pediatric Population: A Systematic Review.","authors":"Deekshitha Alla, Dhruv Jayeshkumar Shah, Muneesh Seepana, Rishabh Baskara Salian, Sai Santhosha Mrudula Alla, Midhun Krishna Mohanan, Mert Sabıroğlu, Mohan Sai Sunith Vegesna, Aradhya Singh, Srajan Gupta, Shushrutha Shivalingappa Rekha","doi":"10.1177/2333794X241248967","DOIUrl":null,"url":null,"abstract":"Objective. Commonly recommended drugs for adults and children include proton pump inhibitors (PPIs), proven effective for treating peptic diseases like stomach ulcers, GERD, and Helicobacter pylori infections in children over 1-year-old. Yet, prolonged PPI use carries higher risks of adverse reactions, prompting this study's analysis. Methods. We have performed a systematic review of 30 articles, which include a total of 762 505 pediatric patients. Results. Adverse effects were encountered in 6.98% of the population. The 5 most common adverse effects were respiratory tract complications, gastrointestinal complications, urinary tract infections, asthma, and ENT infections. Conclusion. Hence, PPIs should be prescribed only when necessary, and physicians should prioritize patient education when considering their use.","PeriodicalId":12576,"journal":{"name":"Global Pediatric Health","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11057350/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global Pediatric Health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/2333794X241248967","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

Abstract

Objective. Commonly recommended drugs for adults and children include proton pump inhibitors (PPIs), proven effective for treating peptic diseases like stomach ulcers, GERD, and Helicobacter pylori infections in children over 1-year-old. Yet, prolonged PPI use carries higher risks of adverse reactions, prompting this study's analysis. Methods. We have performed a systematic review of 30 articles, which include a total of 762 505 pediatric patients. Results. Adverse effects were encountered in 6.98% of the population. The 5 most common adverse effects were respiratory tract complications, gastrointestinal complications, urinary tract infections, asthma, and ENT infections. Conclusion. Hence, PPIs should be prescribed only when necessary, and physicians should prioritize patient education when considering their use.

查看原文本刊更多论文

质子泵抑制剂在儿科人群中的安全性：系统回顾

目的。成人和儿童常用的推荐药物包括质子泵抑制剂（PPIs），经证实可有效治疗消化道疾病，如胃溃疡、胃食管反流病，以及 1 岁以上儿童的幽门螺旋杆菌感染。然而，长期服用 PPI 会带来较高的不良反应风险，因此本研究对其进行了分析。研究方法我们对 30 篇文章进行了系统性回顾，共纳入 762 505 名儿科患者。结果显示6.98%的患者出现了不良反应。最常见的 5 种不良反应是呼吸道并发症、胃肠道并发症、尿路感染、哮喘和耳鼻喉科感染。结论因此，只有在必要时才应处方 PPIs，医生在考虑使用时应优先考虑患者教育。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Global Pediatric Health Nursing-Pediatrics

CiteScore

2.20

自引率

0.00%

发文量

105

审稿时长

12 weeks